In the ESME cohort (a real-life cohort describing the daily practice in French cancer centers and hospitals), the prevalence is significantly higher in HER2-positive and triple-negative patients (49% and 38%, respectively) as compared to ER+ HER2− (19%) and ER+ HER2+ (34%) [75]. The gene discussed is ERBB2; the disease is cancer.